Free Newsletter
Health groups try to steer FDA choice
We already know about the heated speculation on the identity of the next FDA commissioner. Now let's talk about the behind-the-scenes lobbying. As the Wall Street Journal reports this morning, health groups are doing some arm-twisting in an attempt to influence the appointment. Some 34 patient advocacy groups and research organizations--most of which get funding from pharma--have formed the FDA Commissioner Coalition and are urging President-elect Obama's transition team to tap someone who's familiar with the industry.
HHS chief-to-be Tom Daschle got a letter from the coalition saying that the next commissioner needs to be free of "pressure from elected and appointed officials and from the news media." And, the letter said, relationships with the pharma industry should be viewed as a "positive qualification" for the post.
Apparently, the groups are trying to undermine the urgings of some in Congress, who've asked Obama to populate FDA with agency outsiders and/or industry critics. Rep. Bart Stupak, who heads up the House Subcommittee on Investigations, wrote Obama in opposition to promoting any current FDA official to the top job; the agency's leadership now is "too close with the industries they regulate."
Even some of the coalition members that signed the letter wish it had included "industry" as one of the possible undue influences at FDA. As Marti Nelson Cancer Foundation's Bob Erwin told the WSJ, "I wish I had corrected the letter to include the importance of resisting pressure from companies, before signing."
- read the WSJ article
Related Articles:
Sharfstein looks to be on FDA short list
Add ex-Waxmanite to FDA hopefuls list
Sweep the FDA clean, Stupak says
Nissen takes a stand with the FDA
Daschle, Waxman nab pharma oversight power
Paid Research Reports
- Trends in mHealth and Telemedicine
- The Global Aesthetic Dermatology Market Outlook
- Future Directions in Regenerative Medicine
- Pipeline Insight: Insulin Antidiabetics – Novel analogs show promise as alternative delivery methods prove less attractive
- Pipeline Insight: Non-insulin Antidiabetics - Rise of the weight-reducers: Once-weekly GLP-1 agonists and novel SGLT-2 inhibitor
- Forecast Insight: Antidiabetics - Diabetes market growth driven by epidemiological trends and rich pipeline


SHARE
WITH: